Dermatology Genome Immune Response Protein 
The Pharma Data
JUNE 19, 2022
This occurs occurs over time as cancer patients are treated with drugs to enhance T-cell mediated immunity,” said Gavin Robertson, professor of pharmacology, pathology, dermatology and surgery, Penn State College of Medicine. Thus, the effect is better p53 pathway activation without the toxic effects seen with MDM inhibitors.
The Pharma Data
AUGUST 11, 2020
In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
The Pharma Data
AUGUST 11, 2020
In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
Expert insights. Personalized for you.
52 
Let's personalize your content